Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion

Coronary Artery Disease Clinical Trial

— MARKOV  

Official title:

Multi-slice CT Scan Assessment of the Impact of PCSK9 Inhibition With Evolocumab on Coronary Perfusion in Patients With Reduced Coronary Fractional Flow Reserve (FFR).

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03851263
• Other study ID #: ECRI-11
• Status: Withdrawn
• Phase: Phase 4
• Start date: August 30, 2019
• Est. completion date: February 24, 2023

Study information

• Verified date: December 2019
• Source: ECRI bv
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The MARKOV study is an investigator-sponsored single arm, prospective study to assess the effect of evolocumab on the improvement in coronary flow (FFRCT) after 18 and 36 months of treatment in patients with coronary atherosclerosis.

Description:

The MARKOV study is an investigator-initiated, open-label, single arm, international, multicenter, prospective study to assess the effect of evolocumab on the improvement in coronary flow (FFRCT) after 18 and 36 months of treatment in patients with coronary atherosclerosis. The study will be conducted in 5 sites in 3 different countries in Europe. Patients will receive evolocumab for approximately 3 year. The expected duration of the entire study from First Subject First Visit to Last Subject Last Follow-up is 46 months (3 year and 10 months).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 24, 2023
• Est. primary completion date: August 27, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. At least 2 coronary vessels suitable for CCTA; vessels fulfilling all requirements below: a. patent main branch b. no previous stent placement

2. At least two of the evaluable vessels with subclinical coronary artery disease as defined non-invasively by CCTA with encroachment of the vessel and either: a. Lesion with visual diameter stenosis (DS) < 50% or, b. Lesion with visual DS = 50% and FFRCT > 0.80;

3. No planned coronary revascularization (during the course of the study) at the time of enrollment;

4. Most recent, taken within 30 days prior to informed consent form (ICF) signature, fasting LDL-C = 80 mg/dL (= 2.07 mmol/L) and on stable statin therapy for at least 30 days at the time of blood sampling, or statin-intolerant or for whom a statin is contraindicated.

5. Subject signed informed consent form

Exclusion Criteria:

1. History of coronary artery bypass surgery, heart transplantation, surgical or percutaneous valve repair and/or replacement

2. New York Heart Association (NYHA) class III or IV heart failure

3. Last known left ventricular ejection fraction <30%

4. Active liver disease or hepatic dysfunction, either known or defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal (ULN)

5. Severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2

6. Active malignancy except for adequately treated non-melanoma skin cancer or other non-invasive or in situ neoplasm (e.g. successfully treated cervical cancer in situ or non-active prostate cancer) Imaging CCTA-related

7. Absence of baseline CCTA obtained in the context of standard clinical care

8. Baseline CCTA not meeting Core Lab quality standards

9. Any contraindication for repeat CCTA such as known anaphylactic allergy to iodinated contrast

Concomitant and study medication

10. Any prior or current use of PCSK9 inhibition treatment or any other experimental lipid-related drug Other exclusion criteria

11. LDL or plasma apheresis within 12 months of screening

12. Subject < 18 years of age

13. Legally incompetent to provide written informed consent;

14. Known pregnancy or breast-feeding at time of screening

15. Female subject of childbearing potential, i.e. who are not surgically sterile or post-menopausal (defined as no menses for 2 years without an alternative cause)

16. Male subject with female partner of childbearing potential who is not using highly effective birth control

17. Currently participating in another trial

Related Conditions & MeSH terms

• Coronary Artery Disease

Intervention

Biological:
• Evolocumab
Subcutaneous injection, using a pre-filled auto-injector pen. Each pen contains 1.0 ml fluid (containing 140 mg evolocumab) which is injected in the abdomen, thigh or outer area of upper arm every 2 weeks (q2w).

Locations

Country	Name	City	State
n/a

Sponsors (4)

Lead Sponsor	Collaborator
ECRI bv	Amgen, GE Healthcare, HeartFlow, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change in normalized area under the curve of fractional flow reserve derived from coronary computed tomography(CCTA) (FFRCT) at 18 months from baseline		18 months of treatment
Secondary	Mean change in normalized area under the curve of fractional flow reserve derived from coronary computed tomography (FFRCT) at 36 months from baseline.		36 months of treatment
Secondary	Percent change of total atheroma burden (TAB) and changes in plaque composition at 18 and 36 months measured by Hounsfield unit of plaque with positive remodeling (>1.10) assessed by coronary computed tomography.		18 and 36 months of treatment
Secondary	Change and percent change after 18 and 36 months from baseline of total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), lipoprotein (a), triglycerides, apolipoprotein A1 and B.		18 and 36 months of treatment
Secondary	Number of treatment emergent adverse events (TEAEs) and adverse events (AEs) of special interest (i.e. acute kidney injury, pregnancy and lactation)		36 months of treatment
Secondary	Incidence of all-cause death and the composite of Cardiovascular death, myocardial infarction, stroke, or coronary revascularization. The composite of Cardiovascular death, Myocardial infarction, or stroke		36 months of treatment